Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of patients after hematopoietic stem cell transplantation

Evaluation of the utility of Abbott RealTime CMV in monitoring CMV infection of patients after hematopoietic stem cell transplantation - Abbott RealTime CMV Domestic Clinical Performance Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036827

Enrollment

Registered

2019-05-24

Start date

2017-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic Stem Cell Transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults of age 20 or older Patients scheduled for Allogeneic hematopoietic stem cell transplantation Consent form obtained

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity in the detection of CMV infection using Abbott RealTime CMV (when antigenemia is a standard method)	—

Countries

Japan

Contacts

Public ContactYutaka Seki

Abbott Japan Co., Ltd. Molecular Division

yutaka.seki@abbott.com03-4555-1099

Outcome results